Roger Barry Clampitt

2018 ◽  
Vol 182 (2) ◽  
pp. 58-58
Author(s):  
Max Murray ◽  
James Armour ◽  
Christopher Little ◽  
Ronald Barron
Keyword(s):  
Clinical Biochemistry ◽  
Outstanding Contribution ◽  
Clinical Pathologist

A clinical pathologist whose outstanding contribution to the profession was to invent the first reliable clinical biochemistry analyser for use in practice.

2008 Outstanding Contribution to Health Psychology "Junior" Award

2008 ◽  
Author(s):  
Annette Stanton
Keyword(s):  
Health Psychology ◽  
Outstanding Contribution

2008 Outstanding Contribution to Health Psychology "Senior" Award

2008 ◽  
Author(s):  
Michael Scheier
Keyword(s):  
Health Psychology ◽  
Outstanding Contribution

2006 Outstanding Contribution to Health Psychology: Senior Award

2006 ◽  
Author(s):  
David Williams
Keyword(s):  
Health Psychology ◽  
Outstanding Contribution

2007 Outstanding Contribution to Health Psychology "Junior" Award

2007 ◽  
Author(s):  
Jennifer A. Haythornthwaite
Keyword(s):  
Health Psychology ◽  
Outstanding Contribution

Film and History: An Interview with Janet Mcbain, Curator of the Scottish Film Archive

2007 ◽  
Vol 27 (1) ◽  
pp. 94-104
Keyword(s):  
Outstanding Contribution ◽  
Historical Preservation ◽  
Film And Television

In November 2006, Janet McBain was awarded a Scottish Bafta by the Scottish section of the British Academy of Film and Television Arts, for ‘outstanding contribution to film in Scotland’. Janet has been the archivist since its foundation in 1976. Here, she talks with the editor about her archive and her own contribution to the development of historical preservation and research into film in Scotland.

The Kenneth E. Iverson award for outstanding contribution to the development and application of APL

2000 ◽  
Vol 31 (1) ◽  
pp. 28
Author(s):  
Jon McGrew
Keyword(s):  
Outstanding Contribution

scholarly journals Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Xavier Ruiz-Plazas ◽  
Esther Rodríguez-Gallego ◽  
Marta Alves ◽  
Antonio Altuna-Coy ◽  
Javier Lozano-Bartolomé ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Biochemistry ◽  
Specific Antigen ◽  
Total Serum ◽  
Mrna Levels ◽  
Biomarker Panel ◽  
Non Invasive ◽  
Clinical Biomarkers ◽  
Cancer Aggressiveness ◽  
Aggressive Tumors

Abstract Background Conventional clinical biomarkers cannot accurately differentiate indolent from aggressive prostate cancer (PCa). We investigated the usefulness of a biomarker panel measured exclusively in biofluids for assessment of PCa aggressiveness. Methods We collected biofluid samples (plasma/serum/semen/post-prostatic massage urine) from 98 patients that had undergone radical prostatectomy. Clinical biochemistry was performed and several cytokines/chemokines including soluble(s) TWEAK, sFn14, sCD163, sCXCL5 and sCCL7 were quantified by ELISA in selected biofluids. Also, the expression of KLK2, KLK3, Fn14, CD163, CXCR2 and CCR3 was quantified by real-time PCR in semen cell sediment. Univariate, logistic regression, and receiver operating characteristic (ROC) analyses were used to assess the predictive ability of the selected biomarker panel in conjunction with clinical and metabolic variables for the evaluation of PCa aggressiveness. Results Total serum levels of prostate-specific antigen (PSA), semen levels of sTWEAK, fasting glycemia and mRNA levels of Fn14, KLK2, CXCR2 and CCR3 in semen cell sediment constituted a panel of markers that was significantly different between patients with less aggressive tumors [International Society of Urological Pathology (ISUP) grade I and II] and those with more aggressive tumors (ISUP grade III, IV and V). ROC curve analysis showed that this panel could be used to correctly classify tumor aggressiveness in 90.9% of patients. Area under the curve (AUC) analysis revealed that this combination was more accurate [AUC = 0.913 95% confidence interval (CI) 0.782–1] than a classical non-invasive selected clinical panel comprising age, tumor clinical stage (T-classification) and total serum PSA (AUC = 0.721 95% CI 0.613–0.830). Conclusions TWEAK/Fn14 axis in combination with a selected non-invasive biomarker panel, including conventional clinical biochemistry, can improve the predictive power of serum PSA levels and could be used to classify PCa aggressiveness.

Sign in / Sign up

Export Citation Format

Share Document